Premium
Incidence of Viral Hepatitis after Administration of Factor IX Concentrates
Author(s) -
Iwarson Sten,
Kjellman Hans,
TegerNilsson AnnCatrine
Publication year - 1976
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.1976.tb02200.x
Subject(s) - medicine , incidence (geometry) , virology , administration (probate law) , factor ix , viral hepatitis , hepatitis , hepatitis c , immunology , mathematics , political science , geometry , law
Abstract. A high frequency of viral hepatitis has been reported after treatment with the human factor IX concentrate ‘Konyne’. Clinical trials with ‘Konyne’ and a similar factor IX concentrate, called ‘Preconativ’, was started in Sweden 1969. During the first 2 years, 26 patients were treated with either one or both preparations. Nine patients developed viral hepatitis within 6 months after treatment. ‘Preconativ’ alone was introduced on the Swedish market in 1971. During the period 1971–1974, another 26 hemophiliacs were treated but only two cases of hepatitis have occurred. Selection of donors and screening for hepatitis B surface antigen in donor blood used for the manufacturing of ‘Preconativ’, might be contributing factors to this low hepatitis incidence.